- KR₩325bn
- KR₩271bn
- KR₩134bn
- 97
- 52
- 40
- 73
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.22 | ||
| PEG Ratio (f) | 0.67 | ||
| EPS Growth (f) | 18.08% | ||
| Dividend Yield (f) | 1.01% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.75 | ||
| Price to Tang. Book | 1.8 | ||
| Price to Free Cashflow | 11.35 | ||
| Price to Sales | 2.42 | ||
| EV to EBITDA | 7.32 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 14.35% | ||
| Return on Equity | 14.84% | ||
| Operating Margin | 21.45% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 72,798.66 | 144,131.04 | 157,707.96 | 118,076.84 | 134,219.24 | 153,500 | 183,500 | 15.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +322.81 | +290.94 | -5.5 | -44.49 | +8.58 | +15.91 | +22.37 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Boditech Med Inc is a Korea-based company principally engaged in the manufacture and sale of medical equipment. The Company is engaged in the manufacture and sale of antigen diagnostic kits and other products. In addition, the Company is engaged in the manufacture and sale of cancer diagnostic kit, drug concentration diagnostic kit and other products. The Company sells its products within domestic market and to overseas markets. The Company was established in 1998 and is located in Chuncheon-si, Gang-won-do, South Korea.
Directors
- Ui Yeol Choi CEO (54)
- Yong Hwan Byun OTH (60)
- Ja Don Gu DRC (41)
- Hu Don Joo DRC (49)
- Gi Bong Nam DRC (59)
- Sang Yeol Park DRC (47)
- Yin Beom Seo NID (48)
- Jong Baek Yim NID (47)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 30th, 2014
- Public Since
- December 29th, 2014
- No. of Shareholders
- 18,349
- No. of Employees
- 1
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Korea Exchange - KOSDAQ- Shares in Issue
- 21,968,796
- Address
- 43, Geodudanji 1-gil, Dongnae-myeon, CHUNCHEON, 24398
- Web
- https://www.boditech.co.kr/en
- Phone
- +82 332431400
- Auditors
- Hanwool Accounting
Upcoming Events for 206640
Similar to 206640
Access Bio
Korea Exchange - KOSDAQ
Aligned Genetics
Korea Exchange - KOSDAQ
Angel Robotics Co
Korea Exchange - KOSDAQ
Asta Co
Korea Exchange - KOSDAQ
Biodyne Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 19:04 UTC, shares in Boditech Med are trading at KR₩14,810. This share price information is delayed by 15 minutes.
Shares in Boditech Med last closed at KR₩14,810 and the price had moved by +22.09% over the past 365 days. In terms of relative price strength the Boditech Med share price has outperformed the FTSE Developed Asia Pacific Index by +27.44% over the past year.
The overall consensus recommendation for Boditech Med is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Boditech Med dividend yield is 1.35% based on the trailing twelve month period.
Last year, Boditech Med paid a total dividend of KR₩200, and it currently has a trailing dividend yield of 1.35%.Looking ahead, the next dividend pay date is 2024-04-22.
We do not have data on when Boditech Med is to next pay dividends. The historic dividend yield on Boditech Med shares is currently 1.35%.
To buy shares in Boditech Med you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩14,810, shares in Boditech Med had a market capitalisation of KR₩325bn.
Here are the trading details for Boditech Med:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 206640
Based on an overall assessment of its quality, value and momentum Boditech Med is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Boditech Med. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -20.31%.
As of the last closing price of KR₩14,810, shares in Boditech Med were trading -13.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Boditech Med PE ratio based on its reported earnings over the past 12 months is 10.22. The shares last closed at KR₩14,810.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Boditech Med's management team is headed by:
- Ui Yeol Choi - CEO
- Yong Hwan Byun - OTH
- Ja Don Gu - DRC
- Hu Don Joo - DRC
- Gi Bong Nam - DRC
- Sang Yeol Park - DRC
- Yin Beom Seo - NID
- Jong Baek Yim - NID